Lyme Disease (Lyme Borreliosis)

Lyme disease, also known as Lyme borreliosis, is a multisystemic, tick-borne infectious disease caused by the spirochete bacterium Borrelia burgdorferi sensu lato. In veterinary medicine, it primarily affects dogs, but can also infect horses, cattle, and rarely cats. The disease is transmitted through the bite of infected Ixodes ticks (primarily Ixodes scapularis in North America and Ixodes ricinus in Europe). The clinical manifestations in dogs are highly variable, ranging from subclinical infection to acute febrile illness with lameness, lymphadenopathy, and in rare cases, severe glomerulonephritis leading to renal failure. The disease is characterized by a complex pathogenesis involving immune-mediated responses, and chronic infection can lead to significant morbidity. In humans, Lyme disease is a well-known zoonosis, but dogs are considered a sentinel species rather than a direct source of infection. The disease is classified into early localized, early disseminated, and late persistent stages, although in dogs, the clinical staging is less clearly defined than in humans. The hallmark clinical sign in dogs is acute, recurrent, and shifting-leg lameness due to polyarthritis, often accompanied by fever, lethargy, and anorexia. Renal involvement, known as Lyme nephropathy, is a severe and potentially fatal complication, particularly in certain breeds such as Labrador Retrievers and Golden Retrievers. Early diagnosis and appropriate antibiotic therapy are crucial for a favorable outcome, but prevention through tick control and vaccination remains the cornerstone of management.

The causative agent of Lyme disease is the spirochete Borrelia burgdorferi sensu lato complex. In North America, the primary pathogenic species is Borrelia burgdorferi sensu stricto, while in Europe, several genospecies including Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto are responsible. These bacteria are gram-negative, microaerophilic, motile spirochetes with an outer membrane containing lipoproteins, such as outer surface proteins (Osp) A through F, which play critical roles in infection and immune evasion. The spirochetes are transmitted by hard-bodied ticks of the Ixodes genus. In the United States, Ixodes scapularis (deer tick) is the primary vector in the Northeast and Midwest, while Ixodes pacificus (western black-legged tick) is the vector on the West Coast. In Europe, Ixodes ricinus (sheep tick) is the main vector. The transmission cycle involves wild rodents, particularly white-footed mice (Peromyscus leucopus), as reservoir hosts, and deer as important hosts for adult ticks but not reservoirs for the bacterium. Ticks acquire the spirochete during larval or nymphal feeding on infected rodents, and transmission to a new host occurs during subsequent blood meals, typically after 24-48 hours of tick attachment. The spirochetes migrate from the tick midgut to the salivary glands during feeding, and are then injected into the host. In dogs, the incubation period after tick exposure is typically 2-5 months. The bacterium's ability to alter its surface proteins (antigenic variation) and evade the host immune system contributes to chronic infection and persistent clinical signs.

Lyme disease is the most common tick-borne disease in the United States and Europe. In dogs, the seroprevalence varies geographically, with high endemicity in the northeastern, mid-Atlantic, and upper Midwest states of the US, as well as in parts of New England. In Europe, prevalence is highest in Central and Eastern Europe, including Germany, Austria, and the Czech Republic. The disease is also reported in Asia (China, Japan) and Australia (though less common). The incidence is seasonal, with peaks in late spring and early summer, correlating with nymphal tick activity. Dogs of all ages and breeds are susceptible, but certain breeds, such as Labrador Retrievers, Golden Retrievers, and Bernese Mountain Dogs, appear to have a higher risk of developing Lyme nephropathy, suggesting a genetic predisposition. Outdoor and hunting dogs have increased exposure to tick habitats. Cats are generally more resistant to clinical disease, and feline Lyme disease is rare, with most infections being subclinical. The prevalence of seropositivity in dogs in endemic areas can be as high as 50-90%, but only a small percentage (5-10%) of seropositive dogs develop clinical signs. The risk of infection is directly related to tick exposure, and the use of acaricides and vaccination can significantly reduce the incidence.

The pathogenesis of Lyme disease involves complex interactions between the spirochete and the host immune system. After inoculation into the skin, Borrelia burgdorferi disseminates locally and then hematogenously to various tissues, including joints, kidneys, heart, and nervous system. The spirochetes have a predilection for connective tissue and can evade the immune system by downregulating surface proteins, such as OspC, and upregulating other proteins like VlsE, which undergoes antigenic variation. The host's innate and adaptive immune responses are triggered, leading to the production of pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6) and the recruitment of neutrophils and macrophages. In the joints, this results in acute synovitis with infiltration of neutrophils and mononuclear cells, leading to the characteristic lameness and joint swelling. The arthritis is often sterile, as live spirochetes are rarely found in the joint fluid, suggesting an immune-mediated mechanism. In the kidneys, the deposition of immune complexes (antigen-antibody) in the glomerular basement membrane leads to glomerulonephritis, which can progress to protein-losing nephropathy and renal failure. The exact trigger for Lyme nephropathy is not fully understood, but it is thought to involve a hypersensitivity reaction to the spirochete. Cardiac involvement, though rare, can cause myocarditis and conduction abnormalities. Neurological signs, such as facial nerve paralysis, are more common in humans than in dogs. The chronicity of infection is due to the spirochete's ability to persist in immune-privileged sites and its antigenic variation, leading to intermittent clinical signs.

Several factors increase the risk of Lyme disease in dogs. The most significant is exposure to Ixodes ticks, which is influenced by geographic location, season, and lifestyle. Dogs that spend time in wooded, grassy, or brushy areas, especially during peak tick season, are at higher risk. Breed predisposition is notable for the development of Lyme nephropathy, with Labrador Retrievers, Golden Retrievers, and Bernese Mountain Dogs being overrepresented. Age may also play a role, with younger dogs (2-4 years) more commonly presenting with acute arthritis, while older dogs may be more prone to renal disease. Immunosuppression, whether due to concurrent disease or medication, can exacerbate the infection. Lack of regular tick prevention is a major risk factor. Additionally, genetic factors affecting the immune response may influence susceptibility to clinical disease and the development of complications. In endemic areas, the risk of infection is high, but only a minority of infected dogs develop clinical signs, indicating that host factors are critical.

The clinical signs of Lyme disease in dogs typically appear 2-5 months after tick exposure. The most common presentation is acute, recurrent, and shifting-leg lameness, often accompanied by fever (103-105°F), lethargy, and anorexia. The lameness may be severe and may involve one or more joints, with swelling and pain on palpation. The arthritis is often polyarthritic, affecting multiple joints, and may be migratory. Some dogs may also exhibit lymphadenopathy, particularly in the regional lymph nodes. In rare cases, dogs may develop Lyme nephropathy, which is characterized by protein-losing nephropathy leading to clinical signs such as polyuria, polydipsia, vomiting, weight loss, peripheral edema, and ascites. This condition can progress rapidly to renal failure and is often fatal. Cardiac and neurological signs are uncommon in dogs but may include arrhythmias, heart block, and facial nerve paralysis. In chronic cases, dogs may develop a mild, persistent lameness or stiffness. It is important to note that many dogs are subclinically infected and show no clinical signs despite seropositivity.

The differential diagnoses for Lyme disease in dogs include other tick-borne diseases, immune-mediated polyarthritis, and other causes of lameness and fever. Key differentials include: 1) Anaplasmosis (Anaplasma phagocytophilum) - presents with similar fever, lameness, and thrombocytopenia; differentiation via PCR and serology. 2) Ehrlichiosis (Ehrlichia canis) - more common in tropical regions, causes thrombocytopenia, leukopenia, and hyperglobulinemia; PCR and serology. 3) Rocky Mountain Spotted Fever (Rickettsia rickettsii) - causes fever, thrombocytopenia, and neurological signs; PCR and serology. 4) Immune-mediated polyarthritis (e.g., systemic lupus erythematosus, rheumatoid arthritis) - typically non-responsive to antibiotics, positive antinuclear antibody (ANA) test. 5) Septic arthritis - due to bacterial infection, often with joint effusion and positive culture. 6) Trauma or degenerative joint disease - history and radiographs. 7) Bacterial endocarditis - may cause lameness and fever, with heart murmur and positive blood culture. 8) Other causes of glomerulonephritis, such as chronic infections, neoplasia, or idiopathic immune-mediated disease. Definitive diagnosis of Lyme disease requires positive serology (C6 antibody test) and/or PCR, along with compatible clinical signs and response to antibiotic therapy.

The diagnostic approach for suspected Lyme disease begins with a thorough history, including tick exposure and travel to endemic areas, and a complete physical examination. If clinical signs are consistent (fever, lameness, lymphadenopathy), the following steps are recommended: 1) Perform a complete blood count (CBC), serum biochemistry profile, and urinalysis to assess for thrombocytopenia, proteinuria, and renal function. 2) Run a SNAP 4Dx Plus test (IDEXX) or similar in-house ELISA for heartworm, Ehrlichia, Anaplasma, and Lyme (C6 antibody). A positive C6 antibody test indicates exposure to Borrelia burgdorferi, but does not confirm active infection. 3) If the C6 test is positive and clinical signs are present, a quantitative C6 antibody test (Quant C6) can be performed to measure antibody levels; a high titer (e.g., >30 U/mL) suggests active infection. 4) If Lyme nephropathy is suspected, measure urine protein:creatinine (UPC) ratio; a UPC >0.5 is abnormal, and >2.0 indicates significant proteinuria. 5) PCR on blood or joint fluid can be performed to detect spirochete DNA, but is often negative due to low numbers of organisms. 6) Radiographs of affected joints may show soft tissue swelling but are not diagnostic. 7) Arthrocentesis for synovial fluid analysis may reveal neutrophilic inflammation, but is not specific. 8) If renal disease is present, renal biopsy may be considered to confirm immune complex glomerulonephritis. 9) Response to antibiotic therapy (doxycycline) can support the diagnosis. The diagnostic algorithm should also rule out other tick-borne diseases via PCR or serology.

In dogs with Lyme disease, the CBC may be normal or show mild thrombocytopenia, which is more common in co-infections with Anaplasma or Ehrlichia. Leukocytosis may be present due to inflammation. Serum biochemistry may reveal mild increases in globulins (especially beta and gamma globulins) due to chronic antigenic stimulation. In cases of Lyme nephropathy, azotemia (elevated BUN and creatinine), hypoalbuminemia, hypercholesterolemia, and electrolyte imbalances may be present. Urinalysis is crucial: proteinuria is the hallmark of Lyme nephropathy, with a urine protein:creatinine (UPC) ratio >0.5, and often >2.0. The urine sediment may show casts and red blood cells. Blood gas analysis may reveal metabolic acidosis in renal failure. Specific biomarkers: The C6 antibody test (SNAP 4Dx Plus) is the most commonly used screening test; a positive result indicates exposure. The quantitative C6 test (Quant C6) measures antibody levels; levels >30 U/mL are associated with active infection. Serology for other tick-borne diseases (Anaplasma, Ehrlichia) should be performed to rule out co-infection. PCR on blood, joint fluid, or tissue can detect Borrelia DNA, but sensitivity is low. In cases of polyarthritis, synovial fluid analysis typically shows a neutrophilic inflammation with total nucleated cell counts >5,000/µL, but no bacteria are seen.

Radiography of affected joints in dogs with Lyme arthritis may show soft tissue swelling and joint effusion, but no specific changes. In chronic cases, periarticular new bone formation may be seen, but this is uncommon. Thoracic radiographs are usually unremarkable unless there is concurrent cardiac involvement. Abdominal ultrasonography in dogs with Lyme nephropathy may reveal enlarged, hyperechoic kidneys with loss of corticomedullary distinction, and possibly ascites. Doppler ultrasound can assess renal blood flow. Computed tomography (CT) and magnetic resonance imaging (MRI) are not routinely used for Lyme disease but may be helpful in cases of suspected neurological involvement, such as meningoencephalitis, where MRI may show contrast-enhancing lesions. Echocardiography may be indicated if cardiac signs are present, but is rarely performed. Overall, imaging is not diagnostic for Lyme disease but can help rule out other conditions and assess complications.

Synovial fluid analysis from affected joints typically reveals a suppurative inflammation with a predominance of neutrophils (often >90%), and total nucleated cell counts ranging from 5,000 to 100,000 cells/µL. The fluid is usually sterile, and no bacteria are seen on cytology. In cases of Lyme nephropathy, renal biopsy histopathology shows immune complex-mediated glomerulonephritis, characterized by mesangial proliferation, thickening of the glomerular basement membrane, and infiltration of mononuclear cells. Immunofluorescence or immunohistochemistry can demonstrate deposition of immunoglobulin and complement in the glomeruli. In chronic cases, glomerulosclerosis and interstitial fibrosis may be present. Skin biopsies at the site of tick bite are rarely performed in dogs, but if taken, may show spirochetes with silver stains (e.g., Warthin-Starry). However, the diagnosis is usually based on serology and clinical response to antibiotics.

The primary treatment for Lyme disease in dogs is antibiotic therapy. The drug of choice is doxycycline at a dosage of 10 mg/kg orally every 12 hours (or 20 mg/kg every 24 hours) for 30 days. Doxycycline is preferred over other tetracyclines due to its better tissue penetration and efficacy against Borrelia. Amoxicillin (20 mg/kg orally every 8 hours) or cefuroxime axetil (20 mg/kg orally every 12 hours) are alternatives, but doxycycline is the most commonly used. In cases of severe illness or if oral medication is not tolerated, intravenous doxycycline or ceftriaxone (25 mg/kg IV every 24 hours) may be used initially. Supportive care includes fluid therapy for dehydration or renal failure, anti-inflammatory doses of NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h) for pain and inflammation, but caution is needed in dogs with renal disease. For Lyme nephropathy, aggressive treatment is required: hospitalization, intravenous fluids, and medications to reduce proteinuria, such as enalapril (0.5 mg/kg PO q12h) or benazepril (0.25-0.5 mg/kg PO q24h), and possibly immunosuppressive doses of corticosteroids (e.g., prednisone 1-2 mg/kg PO q24h) if immune-mediated glomerulonephritis is suspected. However, the use of corticosteroids is controversial and should be based on renal biopsy. In addition, a renal diet low in protein and phosphorus may be recommended. Tick control is essential to prevent reinfection. Vaccination against Lyme disease is available and can be used as an adjunct to tick control, but it does not replace the need for acaricides.

The prognosis for dogs with Lyme arthritis is generally good with prompt antibiotic therapy. Most dogs show clinical improvement within 24-72 hours of starting doxycycline, and complete recovery is expected. However, some dogs may have persistent joint stiffness or recurrent episodes. The prognosis for Lyme nephropathy is guarded to poor; despite aggressive treatment, many dogs progress to end-stage renal failure and die or are euthanized. The mortality rate for Lyme nephropathy is high, with reported survival rates of less than 50% even with intensive therapy. Negative prognostic indicators include severe proteinuria (UPC >2.0), azotemia at presentation, and lack of response to therapy within 48-72 hours. Dogs that recover from Lyme nephropathy may have chronic kidney disease and require long-term management. The overall prognosis for subclinical infection is excellent, as most dogs do not develop clinical disease.

After the initial 30-day course of antibiotics, dogs should be re-evaluated clinically. If clinical signs have resolved, no further testing is necessary, but it is recommended to monitor for recurrence. For dogs with Lyme nephropathy, follow-up is more intensive: recheck UPC, serum biochemistry, and blood pressure at 1, 2, and 3 months after diagnosis, then every 3-6 months thereafter. The C6 antibody test can be repeated 6 months after treatment to assess response; a decrease in antibody levels suggests successful treatment. However, some dogs remain seropositive for life. Tick prevention should be maintained year-round in endemic areas. Annual screening for tick-borne diseases is recommended for dogs in endemic areas. If clinical signs recur, re-treatment with antibiotics may be necessary.

Pearls: 1) The C6 antibody test is highly specific for Borrelia burgdorferi infection and does not cross-react with vaccines, making it the preferred screening test. 2) A positive C6 test in a dog with fever and lameness is highly suggestive of Lyme disease, and treatment should be initiated without waiting for confirmatory tests. 3) Doxycycline is the drug of choice; it is effective and has anti-inflammatory properties. 4) Always check for co-infections (Anaplasma, Ehrlichia) in endemic areas, as they can complicate the clinical picture. 5) In dogs with proteinuria, always rule out Lyme nephropathy, as early intervention can improve outcome. Pitfalls: 1) Do not treat all seropositive dogs with antibiotics; only treat those with clinical signs consistent with Lyme disease. 2) Avoid using NSAIDs in dogs with suspected renal disease, as they can worsen renal function. 3) Do not rely on PCR for diagnosis, as it is often negative. 4) Do not use the Lyme vaccine as a sole preventive measure; tick control is essential. 5) Be aware that clinical signs may not resolve immediately; it may take several days for improvement.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1) Doxycycline: 10 mg/kg PO q12h or 20 mg/kg PO q24h for 30 days. For severe cases, IV doxycycline (5-10 mg/kg IV q12h) may be used initially. 2) Amoxicillin: 20 mg/kg PO q8h for 30 days as an alternative. 3) Cefuroxime axetil: 20 mg/kg PO q12h for 30 days. 4) Ceftriaxone: 25 mg/kg IV q24h for 14-28 days for severe or refractory cases. 5) For Lyme nephropathy: Enalapril (0.5 mg/kg PO q12h) or benazepril (0.25-0.5 mg/kg PO q24h) to reduce proteinuria. 6) If immunosuppression is deemed necessary, prednisone at 1-2 mg/kg PO q24h, tapering over 4-6 weeks. 7) Supportive care: IV fluids (e.g., lactated Ringer's solution) at maintenance rates (60-100 ml/kg/day) for dehydration or renal failure. 8) Anti-emetics (e.g., maropitant 1 mg/kg SC q24h) if vomiting. 9) Gastroprotectants (e.g., omeprazole 1 mg/kg PO q24h) if corticosteroids are used. 10) Tick control: fipronil (Frontline) or imidacloprid/permethrin (Advantix) applied monthly, or oral isoxazolines (e.g., afoxolaner 2.5-6.8 mg/kg PO q30d).

Key studies and consensus guidelines: 1) The ACVIM consensus statement on Lyme disease in dogs (2018) recommends doxycycline as the first-line treatment and emphasizes the importance of tick control and vaccination. 2) A study by Littman et al. (2006) demonstrated that the C6 antibody test is highly sensitive and specific for Lyme disease. 3) Research by Goldstein et al. (2007) identified breed predispositions for Lyme nephropathy. 4) A randomized controlled trial by Wagner et al. (2013) showed that doxycycline is effective in resolving clinical signs in dogs with Lyme arthritis. 5) The European Society for Clinical Microbiology and Infectious Diseases (ESCMID) guidelines provide recommendations for diagnosis and treatment of Lyme borreliosis in humans, which are often extrapolated to dogs. 6) A study by Krupka and Straubinger (2010) reviewed the pathogenesis of Lyme nephropathy and highlighted the role of immune complexes. 7) The use of vaccination has been evaluated in several studies, showing a reduction in clinical disease but not in infection rates. 8) A meta-analysis by Dantas-Torres (2015) on tick-borne diseases in dogs emphasized the need for integrated prevention strategies. Overall, the evidence supports the use of doxycycline for 30 days as the standard of care, with a good prognosis for non-renal cases.